Posted opportunity — confirm at source
Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
National Institutes of Health · PAR-25-444
See source for award amount
2028-09-25-00-00-00
Confirm exact timezone in the announcement.Public and State controlled institutions of higher education, Private institutions of higher education, County governments, City or township governments, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Small businesses, Others (see text field entitled "Additional Information on Eligibility" for clarification), Independent school districts, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Native American tribal organizations (other than Federally recognized tribal governments), For profit organizations other than small businesses, Native American tribal governments (Federally recognized), State governments, Special district governments
Geographic eligibility and all attachment-specific conditions require review of the original announcement.
Eligibility details
Specific to this NOFO:For New (Type 1) applications, an applicant institution must have a funding base of $10,000,000 (Clinical Cancer Centers) or $6,000,000 (Basic Cancer Centers) in annual direct costs of NIH funding that is cancer-focused, as defined by the Research Condition and Disease Categorization (RCDC) system. Please contact the NCI Office of Cancer Centers (https://cancercenters.cancer.gov/) for assistance in determining the RCDC funding base.For Renewal (Type 2) applications, an applicant institution must have a funding base of at least $10,000,000 in annual direct costs of peer-reviewed, cancer-related funding. If the Cancer Center is an approved consortium of institutions, the funding base of the Center will be the sum of the funding bases of all participating institutions. However, funding (and other data) awarded to consortium partners may be included only if the partner has been previously evaluated in CCSG peer-review and approved by NCI.Example of NCI peer-reviewed mechanisms that may be included for determining eligibility to apply for a CCSG: DP1, DP2, R00, R01, R03, R15, R18, R21, R24, R25, R33, R35, R37, R41, R42, R50, R55, R56, P01, P20, P30s other than the CCSG, P50, SC1, SC2, U01, U10, U19, U24, U54, U56, UH2, UH3, UG3, T32, K and F series awards and N01s (excluding SEER and other N01s funding materials, services, or research resources). Cancer-relevant research funded by these mechanisms from other NIH Institutes may also be counted towards the minimum, as do cancer-relevant grants and contracts from the peer-reviewed funding sources listed in: https://cancercenters.cancer.gov/sites/default/files/PeerReviewFundingOrganizations.pdfNOTE: New (Type 1) applications cannot request evaluation for comprehensiveness status.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Matching funds & resources
Source matching-funds field: Not Required.
Matching funds and leveraged resources are different requirements. Read the description and reviewed rules below before determining resource commitments.
About this opportunity
This Notice of Funding Opportunity (NOFO) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-Designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research. The purpose of all types of NCI-Designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this NOFO are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.
Funding geography: Not specified — review source. A funder’s address does not establish eligibility.
Review original source ↗Funding instrument: Grant. Issuing jurisdiction: Federal. This is not a geographic eligibility determination.
Source fields and evidence
id: 360918
Source ↗ · id
opportunityNumber: PAR-25-444
Source ↗ · opportunityNumber
opportunityTitle: Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
Source ↗ · opportunityTitle
revision: 1
Source ↗ · revision
agencyDetails: {"code":"NIH","seed":"HHS-NIH11","agencyName":"National Institutes of Health","agencyCode":"HHS-NIH11","topAgencyCode":"HHS"}
Source ↗ · agencyDetails
owningAgencyCode: HHS-NIH11
Source ↗ · owningAgencyCode
cfdas: [{"id":431496,"opportunityId":360918,"cfdaNumber":"93.397","programTitle":"Cancer Centers Support Grants"},{"id":431497,"opportunityId":360918}]
Source ↗ · cfdas
applicantTypes: [{"id":"06","description":"Public and State controlled institutions of higher education"},{"id":"20","description":"Private institutions of higher education"},{"id":"01","description":"County governments"},{"id":"02","description":"City or township governments"},{"id":"12","description":"Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education"},{"id":"23","description":"Small businesses"},{"id":"25","description":"Others (see text field entitled \"Additional Information on Eligibility\" for clarification)"},{"id":"05","description":"Independent school districts"},{"id":"13","description":"Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education"},{"id":"11","description":"Native American tribal organizations (other than Federally recognized tribal governments)"},{"id":"22","description":"For profit organizations other than small businesses"},{"id":"07","description":"Native American tribal governments (Federally recognized)"},{"id":"00","description":"State governments"},{"id":"04","description":"Special district governments"}]
Source ↗ · applicantTypes
applicantEligibilityDesc: Specific to this NOFO:For New (Type 1) applications, an applicant institution must have a funding base of $10,000,000 (Clinical Cancer Centers) or $6,000,000 (Basic Cancer Centers) in annual direct costs of NIH funding that is cancer-focused, as defined by the Research Condition and Disease Categorization (RCDC) system. Please contact the NCI Office of Cancer Centers (https://cancercenters.cancer.gov/) for assistance in determining the RCDC funding base.For Renewal (Type 2) applications, an applicant institution must have a funding base of at least $10,000,000 in annual direct costs of peer-reviewed, cancer-related funding. If the Cancer Center is an approved consortium of institutions, the funding base of the Center will be the sum of the funding bases of all participating institutions. However, funding (and other data) awarded to consortium partners may be included only if the partner has been previously evaluated in CCSG peer-review and approved by NCI.Example of NCI peer-reviewed mechanisms that may be included for determining eligibility to apply for a CCSG: DP1, DP2, R00, R01, R03, R15, R18, R21, R24, R25, R33, R35, R37, R41, R42, R50, R55, R56, P01, P20, P30s other than the CCSG, P50, SC1, SC2, U01, U10, U19, U24, U54, U56, UH2, UH3, UG3, T32, K and F series awards and N01s (excluding SEER and other N01s funding materials, services, or research resources). Cancer-relevant research funded by these mechanisms from other NIH Institutes may also be counted towards the minimum, as do cancer-relevant grants and contracts from the peer-reviewed funding sources listed in: https://cancercenters.cancer.gov/sites/default/files/PeerReviewFundingOrganizations.pdfNOTE: New (Type 1) applications cannot request evaluation for comprehensiveness status.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Source ↗ · applicantEligibilityDesc
fundingInstruments: [{"id":"G","description":"Grant"}]
Source ↗ · fundingInstruments
fundingActivityCategories: [{"id":"HL","description":"Health"}]
Source ↗ · fundingActivityCategories
awardFloor: none
Source ↗ · awardFloor
awardCeiling: none
Source ↗ · awardCeiling
responseDate: Sep 25, 2028 12:00:00 AM EDT
Source ↗ · responseDate
responseDateStr: 2028-09-25-00-00-00
Source ↗ · responseDateStr
costSharing: false
Source ↗ · costSharing
lastUpdatedDate: Jan 05, 2026 11:48:39 AM EST
Source ↗ · lastUpdatedDate
status: posted
Source ↗ · oppHits[id=360918].oppStatus
Build your funding pipeline.
Save opportunities, filter by fit, and export your deadlines with membership.
View plans from $49/month ↗